

The Board:

1. *Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B35/ERO3 ("Table 1");*
2. *Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;*
3. *Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and*
4. *Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.*

This decision does not have material budgetary implications for the 2016 Operating Expenses Budget.

01 Table 1: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation

N	Country	Disease Component	Grant Name	Currency	Grant End Date	Total Program Budget	Existing Funding	Incremental Amount for Board Approval	Recommended Total Incremental Funding	Incentive Funding Included in Total Incremental Funding	Unfunded Quality Demand	Domestic commitment
1	Afghanistan	HIV/AIDS	AFG-H-UNDP	US\$	31 December 2017	8,690,986	436,790	8,254,196	8,254,196	0	0	n/a
2	Lesotho	TB/HIV	LSO-C-MOF	US\$	30 June 2018	64,412,923	51,982,822	4,169,061	10,280,120	3,149,164	0	93.5 million
			LSO-C-PACT	US\$	30 June 2018		2,149,981	6,111,059				
3	Madagascar	HIV/AIDS	MDG-H-PSI	US\$	31 December 2017	17,640,077	3,220,558	4,883,096	11,762,755	5,489,635	0	16.7 million
			MDG-H-SECNLS	US\$	31 December 2017		2,656,764	6,879,659				
4	Malaysia	HIV/AIDS	MYS-H-MAC	US\$	31 December 2018	2,849,843	2,849,843	0	0	0	0	157.2 million
5 ¹	Namibia	Malaria	NMB-202-Go3-M	US\$	31 December 2017	4,507,867*	3,989,181	518,686	518,686	n/a	n/a	12.39 million
6	Nepal ²	HIV/AIDS	NEP-H-SCF	US\$	15 March 2018	23,959,687	12,563,099	11,396,588	11,396,588	n/a	0	2.05 million
7		Malaria	NPL-M-SCF	US\$	15 March 2018	9,288,714	8,927,648	361,066	361,066	n/a	0	1.45 million
8		TB	NPL-T-SCF	US\$	15 March 2018	11,136,542	7,971,507	3,165,035	3,165,035	n/a	0	10.8 million
9	Pakistan	HSS	PAK-S-HPSIU	US\$	30 June 2018	6,363,846	0	6,363,846	6,363,846	0	0	94 million
10	Peru	TB	PER-T-SES	US\$	30 June 2019	13,858,066	2,125,624	11,732,442	11,732,442	0	0	330.8 million

¹ The Namibia malaria grant is a simplified application with no material reprogramming.

² The Nepal HIV, malaria and TB grants were submitted collectively as a simplified application in order to conduct program reviews, develop national strategic plans and mobilize partnerships in preparation for the next funding cycle.

11	REDCA+	HIV/AIDS	QRC-H-SISCA	US\$	30 June 2019	3,350,971	172,829	3,178,142	3,178,142	n/a	0	n/a
12	Uzbekistan	HIV/AIDS	UZH-H-RAC	US\$	30 June 2018	16,471,723	281,637	16,190,086	16,190,086	0	0	29.5 million